Review

anti scd1 (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech anti scd1
Anti Scd1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 172 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+scd/SCD+Antibody/pmc12956355-47-39-41
Average 96 stars, based on 172 article reviews

anti scd1 - by Bioz Stars, 2026-10

96/100 stars

Images

other:

Article Title: Identification and experimental validation of Stearoyl-CoA desaturase is a new drug therapeutic target for osteosarcoma.
Article Snippet: Osteosarcoma (OS) is the most common malignant bone tumor.. Fatty acid reprogramming plays an essential role in OS progression.. However, new fatty acid related therapeutic targets of OS have not been completely elucidated.

Article Title: Dietary manganese supplementation decreases hepatic lipid deposition by regulating gene expression and enzyme activity involved in lipid metabolism in the liver of broilers.
Article Snippet: This study aimed to characterize the effects of different dietary forms of supplemental manganese (Mn) on hepatic lipid deposition, gene expression, and enzyme activity in liver fat metabolism in 42-d-old broiler chickens.. In total 420 one-day-old Arbor Acres (AA) broilers (rooster:hen = 1:1) were assigned randomly based on body weight and sex to 1 of 6 treatments (10 replicate cages per treatment and 7 broilers per replicate cage) in a completely randomized design using a 2 (sex) × 3 (diet) factorial arrangement.. The 3 diets were basal control diets without Mn supplementation and basal diets supplemented with either Mn sulfate or Mn proteinate.

Article Title: Peptostreptococcus anaerobius promotes cervical cancer angiogenesis by upregulating SCD to activate ERK pathway
Article Snippet: The primary antibodies included anti-SCD (Proteintech, 1:10000 dilution), anti-p-ERK1/2 (Abmart, 1:1000 dilution), anti-ERK1/2 (Abclonal, 1:1000 dilution), anti-Tubulin (Proteintech, 1:20000 dilution).

Article Title: Matrix stiffness boosts PDAC chemoresistance via SCD1-dependent lipid metabolic reprogramming
Article Snippet: As follows: anti-SCD (1:200, 28678-1-AP; Proteintech), anti-ACLY (1:100, 67166-1-lg; proteintech), anti-FASN (1:200, 10624-2-AP; Proteintech), anti-ACC1 (1:100, 21923-1-AP; Proteintech), anti-ABCC1 (1:100, ab233383; Abcam), anti-ABCC3 (1:200, ab204322; Abcam) and anti-Piezo1 (1:200, 15939-1-AP; Proteintech).

Incubation:

Article Title: Betaine decreases hepatic lipid deposition through DNA 5 mC and RNA m 6 A methylation-mediated regulation of fatty acid metabolic genes expression in laying hens.
Article Snippet: Forty micrograms proteins were separated by SDS-PAGE (ET15420Gel, ACE, Changzhou, China), and then electrotransferred to PVDF membranes (IPFL00010, Merck Millipore, Darmstadt, Germany). .. The resulting membranes were blocked for 2 h at room temperature using 5 % non-fat milk, and then incubated overnight at 4◦C with primary antibodies, including antiSREBP1 (Source: Rabbit, Proteintech,14088-1-AP, 1:1000), anti-SCD (Source: Rabbit, Proteintech, 28678-1-AP, 1:3000), anti-ATGL (Source: Rabbit, Proteintech, 55190-1-AP, 1:3000), anti-CD36 (Source: Rabbit, Proteintech, 18836-1-AP, 1:500), anti-PPARα (Source: Mouse, Proteintech, 66826-1-Ig, 1:2000), CPT1A (Source: Rabbit, Proteintech, 15184-1-AP, 1:2000), ApoB (Source: Rabbit, Proteintech, 20578-1-AP, 1:1000) and β-tubulin (Source: Mouse, Huaxinbio, HX1829, 1:10000). ..

Article Title: Betaine decreases hepatic lipid deposition through DNA 5 mC and RNA m 6 A methylation-mediated regulation of fatty acid metabolic genes expression in laying hens
Article Snippet: Forty micrograms proteins were separated by SDS-PAGE (ET15420Gel, ACE, Changzhou, China), and then electrotransferred to PVDF membranes (IPFL00010, Merck Millipore, Darmstadt, Germany). .. The resulting membranes were blocked for 2 h at room temperature using 5 % non-fat milk, and then incubated overnight at 4°C with primary antibodies, including anti-SREBP1 (Source: Rabbit, Proteintech,14088-1-AP, 1:1000), anti-SCD (Source: Rabbit, Proteintech, 28678-1-AP, 1:3000), anti-ATGL (Source: Rabbit, Proteintech, 55190-1-AP, 1:3000), anti-CD36 (Source: Rabbit, Proteintech, 18836-1-AP, 1:500), anti-PPARα (Source: Mouse, Proteintech, 66826-1-Ig, 1:2000), CPT1A (Source: Rabbit, Proteintech, 15184-1-AP, 1:2000), ApoB (Source: Rabbit, Proteintech, 20578-1-AP, 1:1000) and β-tubulin (Source: Mouse, Huaxinbio, HX1829, 1:10000). ..

Recombinant:

Article Title: CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD
Article Snippet: .. Antibodies were diluted in antibody dilution buffer (Cat. #PS119L, EpiZyme) as follows: anti-CCDC137 (1:1000; Cat. #27201-1-AP, Proteintech), anti-β-actin (1:10000; Cat. #GXP6564, Genxspan), anti-SCD (1:3000; Cat. #28678-1-AP, Proteintech), anti-AKT (1:5000; Cat. #10176-2-AP, Proteintech), anti-p-AKT (1:5000; Cat. #66444-1-Ig, Proteintech), HRP-Goat Anti-Mouse Recombinant Secondary Antibody (1:10,000; Cat. #RGAM001, Proteintech), HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (1:10,000; Cat. #RGAR001, Proteintech). .. The shCCDC137 lentiviral particles and corresponding control lentiviral particles (shCtrl) were purchased from Genechem Co., Ltd (Shanghai, China).

Article Title: CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD.
Article Snippet: .. Antibodies were diluted in antibody dilution buffer (Cat. #PS119L, EpiZyme) as follows: anti-CCDC137 (1:1000; Cat. #27201-1-AP, Proteintech), anti-β-actin (1:10000; Cat. #GXP6564, Genxspan), anti-SCD (1:3000; Cat. #28678- 1-AP, Proteintech), anti-AKT (1:5000; Cat. #10176-2-AP, Proteintech), anti-p-AKT (1:5000; Cat. #66444-1-Ig, Proteintech), HRP-Goat Anti-Mouse Recombinant Secondary Antibody (1:10,000; Cat. #RGAM001, Proteintech), HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (1:10,000; Cat. #RGAR001, Proteintech). .. Establishment of stably transfected cell lines The shCCDC137 lentiviral particles and corresponding control lentiviral particles (shCtrl) were purchased from Genechem Co., Ltd (Shanghai, China).

Image Search Results

PSM upregulates hepatic SCD1 by enriching L. johnsonii . (a) Relative gene expression of hepatic SCD1 ( n =6). (b) Hepatic protein level of SCD1 was assessed by Western blotting and the densitometric quantification ( n =3). (c) Schematic diagram of the mouse experiment. (d) Relative expression of hepatic SCD1 and its upstream regulatory genes ( n =6). (e) Protein level of hepatic SCD1 in the CTRL, PSM alone and ABX+PSM groups, along with densitometric quantification ( n =3). (f) Relative abundance of altered microbiota by PSM alone at the genus level ( n =6). (g) Relative abundance of three Lactobacillus species in stool samples quantified by QPCR ( n =5). (h) Differential abundance of the fecal microbiota at the species level ( n =6). (i) Relative abundance of L. johnsonii was increased in the PSM alone group ( n =6). (j) Relative abundance of L. johnsonii in each group ( n =6). (k) Correlation analysis of the relative abundance of L. johnsonii and hepatic SCD1 protein expression. (l) Growth curves of L. johnsonii cultured with different concentrations of PSM at the indicated time points ( n =3). (m) Bacterial colony counts of L. johnsonii . *, # p < 0.05, *, ## p < 0.01, *, ### p < 0.001.

Journal: Gut Microbes

Article Title: Lactobacillus johnsonii mediates the protective effects of pristimerin against ulcerative colitis and concomitant liver injury through remodeling hepatic lipid metabolism via LXRα–SCD1 axis

doi: 10.1080/19490976.2026.2701349

Figure Lengend Snippet: PSM upregulates hepatic SCD1 by enriching L. johnsonii . (a) Relative gene expression of hepatic SCD1 ( n =6). (b) Hepatic protein level of SCD1 was assessed by Western blotting and the densitometric quantification ( n =3). (c) Schematic diagram of the mouse experiment. (d) Relative expression of hepatic SCD1 and its upstream regulatory genes ( n =6). (e) Protein level of hepatic SCD1 in the CTRL, PSM alone and ABX+PSM groups, along with densitometric quantification ( n =3). (f) Relative abundance of altered microbiota by PSM alone at the genus level ( n =6). (g) Relative abundance of three Lactobacillus species in stool samples quantified by QPCR ( n =5). (h) Differential abundance of the fecal microbiota at the species level ( n =6). (i) Relative abundance of L. johnsonii was increased in the PSM alone group ( n =6). (j) Relative abundance of L. johnsonii in each group ( n =6). (k) Correlation analysis of the relative abundance of L. johnsonii and hepatic SCD1 protein expression. (l) Growth curves of L. johnsonii cultured with different concentrations of PSM at the indicated time points ( n =3). (m) Bacterial colony counts of L. johnsonii . *, # p < 0.05, *, ## p < 0.01, *, ### p < 0.001.

Article Snippet: Animal experiment 6 : PPARα KO-induced increase in hepatic SCD1 expression protected against colitis study, male 129/Sv wild-type mice (WT) were randomly classified into three groups ( n =5): (1) WT-CTRL, (2) WT-DSS, and (3) WT-DSS+Wy14643 (MCE, cat#:50892-23-4).

Techniques: Gene Expression, Western Blot, Expressing, Cell Culture

L. johnsonii activates hepatic LXRα–SCD1 signaling to ameliorate liver injury and colitis. (a) Schematic diagram of the mouse experiment. (b) Relative expression of LXRα downstream target genes ( n =6). (c) Levels of LXRα–SCD1 signaling pathway-related proteins in mice liver ( n =3). (d) Hepatic immunohistochemistry staining showed increased protein expression (LXRα, SREBP1, FASN and SCD1) by culture supernatant of L. johnsonii (Ljsup) ( n =3). (e) Relative abundance of liver LPC species altered by Ljsup ( n =5–6). (f) Serum LPS, TC and TG concentrations ( n =6). (g) Correlation analysis of differential LPC and LPE species with the serum TC, TG concentrations and hepatic SCD1 protein expression. (h, i) Body weight changes and disease activity index (DAI) during the experiment ( n =6). (j) Colon length, spleen and cecum index on day 8 ( n =6). (k) Representative H&E and AB/PAS staining of distal colon sections (scale bar, 100 µm) ( n =3). (l) Ljsup supplementation reduced the relative expression of colonic inflammatory cytokines ( n =6). (m) Ljsup supplementation increased the relative expression of colonic ZO-1 ( n =6). *, # p < 0.05, **, ## p < 0.01, ***, ### p < 0.001.

Journal: Gut Microbes

doi: 10.1080/19490976.2026.2701349

Figure Lengend Snippet: L. johnsonii activates hepatic LXRα–SCD1 signaling to ameliorate liver injury and colitis. (a) Schematic diagram of the mouse experiment. (b) Relative expression of LXRα downstream target genes ( n =6). (c) Levels of LXRα–SCD1 signaling pathway-related proteins in mice liver ( n =3). (d) Hepatic immunohistochemistry staining showed increased protein expression (LXRα, SREBP1, FASN and SCD1) by culture supernatant of L. johnsonii (Ljsup) ( n =3). (e) Relative abundance of liver LPC species altered by Ljsup ( n =5–6). (f) Serum LPS, TC and TG concentrations ( n =6). (g) Correlation analysis of differential LPC and LPE species with the serum TC, TG concentrations and hepatic SCD1 protein expression. (h, i) Body weight changes and disease activity index (DAI) during the experiment ( n =6). (j) Colon length, spleen and cecum index on day 8 ( n =6). (k) Representative H&E and AB/PAS staining of distal colon sections (scale bar, 100 µm) ( n =3). (l) Ljsup supplementation reduced the relative expression of colonic inflammatory cytokines ( n =6). (m) Ljsup supplementation increased the relative expression of colonic ZO-1 ( n =6). *, # p < 0.05, **, ## p < 0.01, ***, ### p < 0.001.

Techniques: Expressing, Immunohistochemistry, Staining, Activity Assay

SR9238 abolishes the liver protection and anti-colitis effects of L. johnsonii . (a) Relative mRNA levels of SREBF1, FASN and SCD1 in HepG2 cells pretreated with insulin (10 µg/ml) for 7 d, followed by 2 µM, 10 µM, and 20 µM SR9238 treatment ( n =3). (b) Schematic diagram of the mouse experiment. (c) Relative expression levels of hepatic SREBF1, FASN and SCD1 in mice ( n =6). (d) Representative images of mice colon, liver and spleen. (e) Masson's trichrome staining showed increased collagen in liver sections (scale bar, 100 µm) ( n =3). (f) Serum TG and TC concentrations ( n =6). (g) Oil Red O staining showed incereased lipid droplet accumulation (scale bar, 100 µm) ( n =3). (h, i) Body weight changes and disease activity index (DAI) changes during the experiment ( n =6). (j) Colon length, spleen and cecum index ( n =6). (k) Representative H&E and AB/PAS staining of distal colon sections (scale bar, 100 µm) ( n =3). (l) SR9238 reduced the relative expression of claudin and occludin in colon tissue ( n =5). *, # p < 0.05, **, ## p < 0.01, ***, ### p < 0.001.

Journal: Gut Microbes

doi: 10.1080/19490976.2026.2701349

Figure Lengend Snippet: SR9238 abolishes the liver protection and anti-colitis effects of L. johnsonii . (a) Relative mRNA levels of SREBF1, FASN and SCD1 in HepG2 cells pretreated with insulin (10 µg/ml) for 7 d, followed by 2 µM, 10 µM, and 20 µM SR9238 treatment ( n =3). (b) Schematic diagram of the mouse experiment. (c) Relative expression levels of hepatic SREBF1, FASN and SCD1 in mice ( n =6). (d) Representative images of mice colon, liver and spleen. (e) Masson's trichrome staining showed increased collagen in liver sections (scale bar, 100 µm) ( n =3). (f) Serum TG and TC concentrations ( n =6). (g) Oil Red O staining showed incereased lipid droplet accumulation (scale bar, 100 µm) ( n =3). (h, i) Body weight changes and disease activity index (DAI) changes during the experiment ( n =6). (j) Colon length, spleen and cecum index ( n =6). (k) Representative H&E and AB/PAS staining of distal colon sections (scale bar, 100 µm) ( n =3). (l) SR9238 reduced the relative expression of claudin and occludin in colon tissue ( n =5). *, # p < 0.05, **, ## p < 0.01, ***, ### p < 0.001.

Techniques: Expressing, Staining, Activity Assay

CORT aggravates colitis with liver injury through the LXRα‒SCD1 axis. (a) Oil Red O staining of AML12 cells treated with 2 µM, 10 µM, and 50 µM CORT. (b) Schematic diagram of the mouse experiment. (c) Protein levels of hepatic CD36, LXRα, FASN, and SCD1 in mice. (d) Representative immunohistochemical staining revealed the decreased protein expression (LXRα, FASN, SCD1, and CD36) in mice ( n =3). (e) Representative images of mice colon, liver and spleen. (f) Representative H&E, Masson's trichrome and Oil Red staining of liver sections (scale bar, 100 µm) ( n =3). (g) Serum TG and TC concentrations ( n =6). (h, i) Body weight changes and disease activity index (DAI) during the experiment ( n =6). (j) CORT reduced colon length ( n =6). (k) Representative H&E and AB/PAS staining of distal colon sections (scale bar, 100 µm) ( n =3). (l) Schematic diagram of the mouse experiment. (m, n) Relative mRNA levels of LXRα target genes. (o) Levels of LXRα signaling pathway-related proteins in mouse liver. (p) Serum TG and TC concentrations ( n =6). (q) Disease activity index (DAI) changes during the experiment ( n =6). (r) Colon length on day 12. * p < 0.05, ** p < 0.01, *** p < 0.001. ns, not significant ( p > 0.05).

Journal: Gut Microbes

doi: 10.1080/19490976.2026.2701349

Figure Lengend Snippet: CORT aggravates colitis with liver injury through the LXRα‒SCD1 axis. (a) Oil Red O staining of AML12 cells treated with 2 µM, 10 µM, and 50 µM CORT. (b) Schematic diagram of the mouse experiment. (c) Protein levels of hepatic CD36, LXRα, FASN, and SCD1 in mice. (d) Representative immunohistochemical staining revealed the decreased protein expression (LXRα, FASN, SCD1, and CD36) in mice ( n =3). (e) Representative images of mice colon, liver and spleen. (f) Representative H&E, Masson's trichrome and Oil Red staining of liver sections (scale bar, 100 µm) ( n =3). (g) Serum TG and TC concentrations ( n =6). (h, i) Body weight changes and disease activity index (DAI) during the experiment ( n =6). (j) CORT reduced colon length ( n =6). (k) Representative H&E and AB/PAS staining of distal colon sections (scale bar, 100 µm) ( n =3). (l) Schematic diagram of the mouse experiment. (m, n) Relative mRNA levels of LXRα target genes. (o) Levels of LXRα signaling pathway-related proteins in mouse liver. (p) Serum TG and TC concentrations ( n =6). (q) Disease activity index (DAI) changes during the experiment ( n =6). (r) Colon length on day 12. * p < 0.05, ** p < 0.01, *** p < 0.001. ns, not significant ( p > 0.05).

Techniques: Staining, Immunohistochemical staining, Expressing, Activity Assay

Protein expression levels ( A , H ) including ( B ) PPARγ, ( C ) Fabp4, ( D ) CD36, ( E ) SREBP-1c, ( F ) ADIPOQ, ( G ) SCD-1, ( I ) TLR4, ( J ) IKKβ, and ( K ) p-P65 in liver tissues among NCD, HFCD, and HFCD + HB-1. Data were expressed as mean ± SD ( n = 3) based on Dunnett’s test. ** indicated p < 0.01, *** indicated p < 0.001, **** indicated p < 0.0001.

Journal: Foods

Article Title: Chemical Composition Analysis of Highland Barley ( Hordeum vulgare L.) with Different Modification Methods and Lipid Metabolism Mechanism Analysis of Highland Barley with Microwave Fluidization Modification

doi: 10.3390/foods15081396

Figure Lengend Snippet: Protein expression levels ( A , H ) including ( B ) PPARγ, ( C ) Fabp4, ( D ) CD36, ( E ) SREBP-1c, ( F ) ADIPOQ, ( G ) SCD-1, ( I ) TLR4, ( J ) IKKβ, and ( K ) p-P65 in liver tissues among NCD, HFCD, and HFCD + HB-1. Data were expressed as mean ± SD ( n = 3) based on Dunnett’s test. ** indicated p < 0.01, *** indicated p < 0.001, **** indicated p < 0.0001.

Article Snippet: The specific antibody concentrations used in this study were as follows: anti-rabbit antibodies against Peroxisome proliferator-activated receptor γ (PPARγ) (1:1000, 58 kDa, Affinity, 16643-1-AP), FABP4 (1:1000, 15 kDa, Affinity, DF6035), CD36 (1:1000, 88 kDa, Affinity, DF13262), SREBP-1c (1:1000, 122 kDa, Affinity, AF6283), ADIPOQ (1:1000, 26 kDa, Affinity, DF7000), SCD-1 (1:1000, 41 kDa, Bioss, bs-3787R), p-P65 (1:1000, 65 kDa, Affinity, AF2006, Serine Ser536), TLR4 (1:1000, 100 kDa, Affinity, AF7017), IKKβ (1:1000, 87 kDa, Affinity, AF6010), and GAPDH (1:1000, 37 kDa, Xianzhi Biotech, AB-P-R 001).

Techniques: Expressing

METTL1-deficient MSCs inhibit lipid synthesis in hepatocytes. (A) Representative images of Nile Red staining in hepatocytes co-cultured with MSC shGFP and MSC shMETTL1 following treatment with FFA (Scale bar = 20 μm). (B) Measurement of TG content in hepatocytes in the indicated groups. (C, D) Western blot analysis of lipid metabolism-related gene expression (FASN, SREBP1, SCD1) in the indicated groups. (E, F) qPCR analysis of lipid synthesis gene expression ( Fasn, Scd1, Srebp1, Fads1 and Acaca ) in AML12 and HepG2 cells co-cultured with MSC shGFP and MSC shMETTL1 . For all statistical graphs, data are presented as mean ± S.E.M, with statistical significance is indicated in the figure.

Journal: Stem Cells Translational Medicine

Article Title: METTL1-deficient mesenchymal stem cells protect against metabolic-associated fatty liver disease by increasing NAMPT secretion

doi: 10.1093/stcltm/szag016

Figure Lengend Snippet: METTL1-deficient MSCs inhibit lipid synthesis in hepatocytes. (A) Representative images of Nile Red staining in hepatocytes co-cultured with MSC shGFP and MSC shMETTL1 following treatment with FFA (Scale bar = 20 μm). (B) Measurement of TG content in hepatocytes in the indicated groups. (C, D) Western blot analysis of lipid metabolism-related gene expression (FASN, SREBP1, SCD1) in the indicated groups. (E, F) qPCR analysis of lipid synthesis gene expression ( Fasn, Scd1, Srebp1, Fads1 and Acaca ) in AML12 and HepG2 cells co-cultured with MSC shGFP and MSC shMETTL1 . For all statistical graphs, data are presented as mean ± S.E.M, with statistical significance is indicated in the figure.

Article Snippet: Primary antibodies specific for the following proteins were obtained from Cell Signaling Technology: ACC-1 (#3676), SCD1 (#2794), FASN (#3180), p-AKT (#4060), and AKT (#9272).

Techniques: Staining, Cell Culture, Western Blot, Gene Expression

Transplantation of METTL1-deficient MSCs alleviates metabolic disorders associated with MASLD. (A) Schematic diagram of the animal experiment. (B) Evaluation of liver weight and the liver-to-body weight ratio in the indicated mice. (C) Assessment of fasting blood glucose levels in the indicated mice. (D) Analysis of GTT and ITT for the indicated groups. (E) Measurement of serum ALT and AST levels following 7 weeks of cell transplantation. (F) Representative images of HE and Oil Red O staining for analysis of mouse liver tissue (Scale bar = 100 μm). (G) Determination of TG and TC levels in the liver tissue of the specified mice. (H) qPCR analysis of lipid synthesis-related genes, including Fasn, Scd1, Srebp1, Fads1 , and Acaca in the specified groups. (I) Western blot analysis of lipid metabolism-related proteins in the specified groups. For all statistical graphs, individual data points represent individual mice, and data are presented as mean ± S.E.M. Statistical significance is indicated as shown in the figure.

Journal: Stem Cells Translational Medicine

Article Title: METTL1-deficient mesenchymal stem cells protect against metabolic-associated fatty liver disease by increasing NAMPT secretion

doi: 10.1093/stcltm/szag016

Figure Lengend Snippet: Transplantation of METTL1-deficient MSCs alleviates metabolic disorders associated with MASLD. (A) Schematic diagram of the animal experiment. (B) Evaluation of liver weight and the liver-to-body weight ratio in the indicated mice. (C) Assessment of fasting blood glucose levels in the indicated mice. (D) Analysis of GTT and ITT for the indicated groups. (E) Measurement of serum ALT and AST levels following 7 weeks of cell transplantation. (F) Representative images of HE and Oil Red O staining for analysis of mouse liver tissue (Scale bar = 100 μm). (G) Determination of TG and TC levels in the liver tissue of the specified mice. (H) qPCR analysis of lipid synthesis-related genes, including Fasn, Scd1, Srebp1, Fads1 , and Acaca in the specified groups. (I) Western blot analysis of lipid metabolism-related proteins in the specified groups. For all statistical graphs, individual data points represent individual mice, and data are presented as mean ± S.E.M. Statistical significance is indicated as shown in the figure.

Article Snippet: Primary antibodies specific for the following proteins were obtained from Cell Signaling Technology: ACC-1 (#3676), SCD1 (#2794), FASN (#3180), p-AKT (#4060), and AKT (#9272).

Techniques: Transplantation Assay, Staining, Western Blot

Review

anti scd1 (Proteintech)

Structured Review

Images

Related Articles

other:

Incubation:

Recombinant:

Similar Products

Image Search Results